C5 and paroxysmal nocturnal hemoglobinuria: A second humanized monoclonal antibody C5 inhibitor, ravulizumab (Alexion Pharmaceuticals), was approved by the Food and Drug Administration (FDA) in December 2018 for the treatment of PNH.